Antiretroviral prophylaxis: a defining moment in HIV control

A defining moment in the global AIDS response has been reached. The discourse is no longer about HIV prevention or HIV treatment; it is now about HIV control through the implementation of antiretrovirals as key components of combination interventions. Barely a year ago, visions of HIV control would have been considered far-fetched. The impetus for this change in mindset, which has been building since the XVIII International AIDS Conference in Vienna last year, emanates from the compelling evidence that antiretroviral drugs prevent HIV infection in the general heterosexual population, which is released this week and presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Rome by the Partners PrEP and Botswana TDF2 trials

Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women

The early closure of a clinical trial assessing the effectiveness of oral antiretroviral pre-exposure prophylaxis (PrEP) in women, FEM-PrEP, is a substantial setback for HIV prevention. Expectations of this trial were high in view of favourable results from the pre-exposure prophylaxis initiative (iPrEX) trial, which studied the same drug and dosing strategy in men who have sex with men, and the Centre for the AIDS Programme of Research in South Africa (CAPRISA 004) trial,3 which tested tenofovir gel (a topical PrEP formulation) in heterosexual women. As a result, the interim FEM-PrEP trial results, announced on April 18, 2011, which showed no protection against HIV infection, were disappointing. Using publicly available information and data from other PrEP studies, we offer a potential explanation for the results of the FEM-PrEP trial

Sero-epidemiology ofhepatitis A in black South African children

A cOIDInunity-based sero-epidemiological survey was undertaken to determine the age-specific prevalence rates of hepatitis A virus (HAV) infection in a representative sample of 782 urban black children aged from newborn to 13 years. Among children aged °-5 months, the prevalence ofantiHAV was 68,8% (95% confidence interval (Cl) 60,6 - 77,0%); this fell to a low of2,5% (Cl 0,1 - 4,9%) in those aged 6 - 11 months, implying the presence of maternal antibody in the first few months of life. By the age of2 years, 51,2% (Cl 45,7 - 56,7%) had anti-HAV, by age 4 the prevalence had risen to 81,4% (Cl 75,5 - 87,3%) and by age 6, the prevalence of anti-HAV was almost 100% (Cl 90,5 96,7%), reflecting the poor socio-economic and environmental conditions these children live in. The lowest prevalence of HAV infection among urban black South African children was during infancy, before the age at which the incidence rate rose sharply; e.g. lout of 5 children was already infected with HAV by its 2nd birthday. Vaccination in infancy will therefore have the biggest impact on the spread of HAV. However, before HAV vaccination in infancy is advocated, vaccine immunogenicity in infancy and the possible detrimental effect of maternal antibodies on the immunogenicity ofthe vaccine need clarification

Stigma impedes AIDS prevention

Thirty years since the first cases of AIDS were described, there is much to celebrate regarding progress in the treatment and prevention of the disease. Within the past year alone, several studies have revealed that antiretroviral drugs can prevent the sexual transmission of HIV. Yet worldwide, many people who are potentially exposed to the virus avoid finding out whether they carry it, or deny that they are at risk of contracting it. Unless people establish whether they are infected, they will not be able to be adopt the most appropriate preventive measures. As scientists and clinicians, our ability to overcome this denialism will determine whether we ultimately succeed in using combinations of all the preventive and therapeutic tools now available to slow, and eventually stop, the HIV/AIDS pandemic

Hepatitis' C virus infection in urban and rural NatallKwaZulu

This study was undertaken to estimate the prevalence of hepatitis C virus (HCV) infection in urban and rural blacks in NataUKwaZulu. Sera from representative community-based samples comprising 176 urban and 441 rural black adults were tested for the presence of anti-HCV. The prevalence of HCV infection was 1,7% (95% confidence interval 0 - 3,6%) among urban and 0,9% (95% confidence interval 0,1 - 1,7% ) among rural blacks. Four (0,9%) of the 466 subjects with evidence of current or past hepatitis B virus (HBV) infection and 3 (2%) of the 151 with no evidence of HBV infection were anti-HCV-positive. The prevalence of HCV infection was low in contrast to the high prevalence of HBV infection among urban and rural blacks in Natal KwaZulu. This suggests that HCV does not have the same main routes of transmission as HBV in this region. Larger scale studies are needed to explore this hypothesis

Underreporting and overreporting of hepatitis B at a tertiary hospital

Objective. To assess the level of underreporting and overreporting of hepatitis B infection at a tertiary hospital.Design. Retrospective record review.Setting. King Edward VIII Hospital, Durban.Main outcome measures. Hepatitis B notification was assessed. Underreporting was ascertained on the basis of the proportion of hepatitis B-positive laboratory results that were not notified. Overreporting was indicated by duplication of notifications and the reporting of patients who have not tested positive for hepatitis B.Results. 83.7% (95% confidence interval 79.4 - 88.0%) of patients with hepatitis B virus infection were not reported. no hospital outpatients were reported and 6% (95% confidence interval 0 - 12.6%) of the reported hepatitis B cases were not hepatitis B.Conclusion. Underreporting of hepatitis B virus infection is the result of an inadequate notification system at a health institution level. A new, user-friendly system of surveillance that actively monitors the reporting rate is recommended to improve the reporting rate and thus generates useful information

Public-private health sector partnerships for STD control in South Africa perspectives from the Hlabisa experience

No Abstrac

SARS-CoV-2 variants and ending the COVID-19 pandemic

International audienc